Trabectedin has promising antineoplastic activity in high-grade meningioma

Cancer

Volumn 118, Issue 20, 2012, Pages 5038-5049

  Preusser, Matthias ^a   Spiegl Kreinecker, Sabine ^b   Lötsch, Daniela ^a,d   Wöhrer, Adelheid ^a,c   Schmook, Maria ^a   Dieckmann, Karin ^a   Saringer, Walter ^a   Marosi, Christine ^a   Berger, Walter ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

antineoplastic; apoptosis; meningioma; therapy; trabectedin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; CYCLINE; HYDROXYUREA; TRABECTEDIN;

ADULT; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BENIGN TUMOR; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CELL CYCLE ARREST; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MALE; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DIOXOLES; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 84867331164     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27460     Document Type: Article

References (42)

1. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK,. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007.
2. Mawrin C, Perry A,. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010; 99: 379-391.
3. Alexiou GA, Gogou P, Markoula S, Kyritsis AP,. Management of meningiomas. Clin Neurol Neurosurg. 2010; 112: 177-182.
4. Modha A, Gutin PH,. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery. 2005; 57: 538-550, 2005; discussion 538-550.
5. Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G,. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics. 2010; 11: 865-878.
6. Carter NJ, Keam SJ,. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs. 2010; 70: 355-376.
7. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001; 92: 583-588.
8. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW,. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res. 2002; 62: 3377-3381.
9. Cai X, Gray PJ Jr, Von Hoff DD,. DNA minor groove binders: back in the groove. Cancer Treat Rev. 2009; 35: 437-450.
10. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001; 19: 1256-1265.
11. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of 2 different schedules. J Clin Oncol. 2009; 27: 4188-4196.
12. Kaye SB, Colombo N, Monk BJ, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol. 2011; 22: 49-58.
13. Preusser M, Heinzl H, Gelpi E, et al. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology. 2008; 53: 39-47.
14. Spiegl-Kreinecker S, Pirker C, Marosi C, et al. Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. Br J Cancer. 2007; 96: 960-969.
15. Heffeter P, Jakupec MA, Korner W, et al. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochem Pharmacol. 2007; 73: 1873-1886.
16. Dornetshuber R, Heffeter P, Kamyar MR, Peterbauer T, Berger W, Lemmens-Gruber R,. Enniatin exerts p53-dependent cytostatic and p53-independent cytotoxic activities against human cancer cells. Chem Res Toxicol. 2007; 20: 465-473.
17. Kubista B, Trieb K, Sevelda F, et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res. 2006; 24: 1145-1152.
18. Pirker C, Lotsch D, Spiegl-Kreinecker S, et al. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465. Exp Dermatol. 2010; 19: 1040-1047.
19. Berger W, Elbling L, Micksche M,. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer. 2000; 88: 293-300.
20. Yu J, Zhang L,. PUMA, a potent killer with or without p53. Oncogene. 2008; 27 (suppl 1): S71-S83.
21. Erba E, Cavallaro E, Damia G, et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res. 2004; 14: 579-587.
22. Marchini S, Marrazzo E, Bonomi R, et al. Molecular characterisation of 2 human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur J Cancer. 2005; 41: 323-333.
23. Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to Yondelis (trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007; 100: 339-348.
24. Scotlandi K, Perdichizzi S, Manara MC, et al. Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res. 2002; 8: 3893-3903.
25. Ghielmini M, Colli E, Erba E, et al. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743). Ann Oncol. 1998; 9: 989-993.
26. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res. 2001; 7: 2908-2911.
27. Takahashi N, Li W, Banerjee D, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 2002; 62: 6909-6915.
28. Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009; 8: 449-457.
29. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001; 7: 961-966.
30. D'Incalci M, Galmarini CM,. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010; 9: 2157-2163.
31. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y,. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res. 2001; 7: 185-191.
32. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001; 37: 97-105.
33. Minuzzo M, Ceribelli M, Pitarque-Marti M, et al. Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters. Mol Pharmacol. 2005; 68: 1496-1503.
34. Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol. 2003; 52: 131-138.
35. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR,. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001; 7: 3251-3257.
36. D'Incalci M, Colombo T, Ubezio P, et al. The combination of Yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer. 2003; 39: 1920-1926.
37. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8: 595-602.
38. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001; 7: 231-242.
39. Kasper B, Schmitt T, Wuchter P, Dimitrakopoulou-Strauss A, Ho AD, Egerer G,. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Mar Drugs. 2009; 7: 331-340.
40. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010; 70: 2235-2244.
41. Chamberlain MC,. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer. 2010; 116: 3988-3999.
42. Puchner MJ, Hans VH, Harati A, Lohmann F, Glas M, Herrlinger U,. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol. 2010; 21: 2445-2446.